This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Truist Financial Initiates a Buy Rating on Viridian Therapeutics (VRDN)
Viridian Therapeutics received a Buy rating and price target from Truist Financial analyst today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
In addition to Truist Financial, Viridian Therapeutics also received a Buy from TD Cowen’s Joseph Thome in a report issued on November 21. However, on November 13, TR | OpenAI – 4o reiterated a Hold rating on Viridian Therapeutics (NASDAQ: VRDN).
Based on Viridian Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $70.57 million and a GAAP net loss of $34.6 million. In comparison, last year the company earned a revenue of $86 thousand and had a GAAP net loss of $76.69 million
Read More on VRDN:
Disclaimer & DisclosureReport an Issue
- Viridian Therapeutics initiated with a Buy at Truist
- Promising Developments and Market Potential Drive Buy Rating for Viridian Therapeutics
- Viridian Therapeutics Advances Toward Profitability with Strategic Moves
- Viridian Therapeutics price target raised to $45 from $41 at RBC Capital
- Viridian Therapeutics price target raised to $40 from $30 at Goldman Sachs
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
